SCHEMBL3088027

SCHEMBL3088027

CCN(CC)c1nc(C)cc(-c2nc(-c3ccc(CCNS(=O)(=O)N(C)C)cc3)no2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
MAPT P10636 6/20 0.35
S1PR1 P21453 5/20 0.35
ALDH1A1 P00352 3/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 3/20 0.34
S1PR3 Q99500 2/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.34
ALOX15 P16050 1/20 0.34
NR1H4 Q96RI1 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3088331 0.91 CA1 (0.40) CA1CA2CA9MAPTS1PR1
SCHEMBL3092682 0.81 S1PR1 (0.47) MAPTS1PR1ALDH1A1S1PR3LMNA
SCHEMBL3086366 0.81 S1PR1 (0.40) MAPTS1PR1ALDH1A1NPC1RAB9A
SCHEMBL3084222 0.81 S1PR1 (0.51) MAPTS1PR1ALDH1A1NPC1RAB9A
SCHEMBL3095704 0.78 S1PR1 (0.48) S1PR1S1PR3
SCHEMBL3086037 0.77 S1PR1 (0.41) MAPTS1PR1ALDH1A1NPC1RAB9A
SCHEMBL1179159 0.75 S1PR1 (0.38) MAPTS1PR1ALDH1A1NPC1RAB9A
SCHEMBL3084808 0.70 S1PR1 (0.46) S1PR1S1PR3
SCHEMBL1179435 0.69 S1PR1 (0.36) MAPTS1PR1ALDH1A1NPC1RAB9A
SCHEMBL1179422 0.68 GRM5 (0.39) MAPTS1PR1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD CA1 4862/4885CA2 4773/4885CA9 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.